Aldeyra Therapeutics

Aldeyra Therapeutics, Inc. operates as a biotechnology company. It primarily focuses on the development of new products for immune-mediated, inflammatory, orphan and other diseases that are thought to be caused in part by naturally occurring toxic chemical species known as free aldehydes. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Aldeyra Therapeutics reports positive milestones and financial stability in Q4 2022

Aldeyra Therapeutics showcased positive performance in key milestones, financial stability, and progress in clinical studies, positioning the company for future growth.
Despite challenges in managing expenses and meeting enrollment deadlines, Aldeyra's strengths in its pipeline and financial position offer opportunities for success.
The upcoming year holds promise for Aldeyra with novel therapies addressing unmet medical needs and significant milestones expected in key trials.
Overall, Aldeyra's focus on advancing treatments for ocular and systemic conditions underscores its commitment to innovation and patient care.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities with related general business planning, including raising capital. It engages in the discovery of therapies designed to treat immune-mediated diseases. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company discovering and developing innovative therapies for the treatment of immune-mediated diseases, today announced completion of enrollment in Part 1 of the Phase 3 GUARD Trial of ADX-2191 (intravitreal methotrexate 0.8%) in patients with proliferative vitreoretinopathy (PVR), a rare, sight-threatening ocular disease with no approved therapy. The GUARD Trial is a two-part, multi-center, r

Aldeyra Therapeutics Completes Enrollment in Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy

Aldeyra Therapeutics reported top-line results from their phase three trial, TRANQUILITY, evaluating Reproxalap in the treatment of dry eye disease; the trial missed the primary endpoint of improving ocular redness.

Aldeyra Therapeutics: Tranquility's Setback Creates A Buying Opportunity If You Believe In Reproxalap

Aldeyra Therapeutics Inc (NASDAQ: ALDX) reported topline data from Phase 3 TRANQUILITY Trial of reproxalap ophthalmic solution for dry eye disease. The trial failed to meet the primary endpoint of ocular redness, but it did achieve statistical significance for the dry eye disease sign of the Schirmer test, a secondary endpoint.

Aldeyra's Dry Eye Disease Candidate Disappoints In Late-Stage Study

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra or the Company), a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases, today announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical sig

Aldeyra Therapeutics Announces Top-Line Results from the Phase 3 TRANQUILITY Trial in Dry Eye Disease

Investors need to pay close attention to Aldeyra (ALDX) stock based on the movements in the options market lately.

Do Options Traders Know Something About Aldeyra (ALDX) Stock We Don't?

Implied Volatility Surging for Aldeyra (ALDX) Stock Options

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra or the Company), a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra, will participate in the following investor conferences: Berenberg US CEO Conference Format: Analyst-Hosted Fireside Chat Date: Wednesday, November 10, 2021 Time: 10:00 a.m. ET Note: A live

Aldeyra Therapeutics to Participate in Upcoming Conferences

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra or the Company), a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases, today announced completion of enrollment in the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap) for the treatment of patients with dry eye disease. “Following the recent announcement of top-line results from our Phase 2 clinical trial, which achieved the pr

Aldeyra Therapeutics Announces Completion of Enrollment in Phase 3 TRANQUILITY Trial in Patients with Dry Eye Disease and Reiterates New Drug Application (NDA) Submission Guidance

Aldeyra Therapeutics Inc's (NASDAQ: ALDX) reproxalap achieved the primary endpoint of ocular redness in the Phase 2 trial in patients with dry eye disease. But the ocular redness scores in the reproxalap group were statistically lower than those of vehicle.

Aldeyra's Dry Eye Disease Trial Meets Primary Endpoint, But Did Not Reach Statistical Significance

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced achievement of the primary endpoint of ocular redness in a randomized, double-masked, vehicle-controlled Phase 2 clinical trial in patients with dry eye disease. The clinical trial enrolled 158 patients: 80 patients were randomized to receive 0.25% reproxalap ophthalmic solution, and 78 patients were randomized to receive vehicle ophthalmic solution. Patients received four doses one day prior

Aldeyra Therapeutics Announces Achievement of Primary Endpoint of Ocular Redness in Randomized, Double-Masked, Vehicle-Controlled Phase 2 Clinical Trial in Dry Eye Disease

Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q3 2021 Results - Earnings Call Transcript

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases, today reported recent corporate highlights and financial results for the quarter ended September 30, 2021. “We continue to make important progress in developing safe and effective treatments for ocular and systemic diseases to improve the lives of patients who have significant unmet medical needs,” sta

Aldeyra Therapeutics Reports Third-Quarter 2021 Financial Results and Recent Corporate Highlights

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call at 8:00 a.m. ET Thursday, October 28, 2021 to report financial results for the quarter ended September 30, 2021 and discuss recent business highlights. The dial-in numbers are (866) 211-4098 for domestic callers and (647) 689-6613 for international callers. The Conference ID number is 8891298. A live webcast of the conference call will also be available on the Investors & Media

Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Third-Quarter 2021 Financial Results and Discuss Recent Business Highlights

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra, will participate in a fireside conversation with Justin Kim, Executive Director, Biotech Equity Research for Oppenheimer & Co. at the virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Wednesday, September 22, 2021 at 9:55 a.m. ET. A live webcast of the conversation will be available

Aldeyra Therapeutics to Participate in the Virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra, will participate in the following investor conferences: Citi's 16th Annual BioPharma Virtual Conference Date: Thursday, September 9, 2021 Time: 8:50 a.m. ET Panel: Eyes on the Prize - Next Generation Reti

Aldeyra Therapeutics to Participate in Upcoming Virtual Investor Conferences

Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q2 2021 Results - Earnings Call Transcript

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases, today reported financial results for the quarter ended June 30, 2021 and recent corporate highlights. “We continue to make meaningful strides toward our goal of developing effective and highly differentiated new therapies to treat ocular and systemic diseases with significant unmet medical need,” state

Aldeyra Therapeutics Reports Second-Quarter 2021 Financial Results and Recent Corporate Highlights

The FDA has granted orphan drug designation to Aldeyra Therapeutics Inc's (NASDAQ: ALDX) ADX-2191 to treat retinitis pigmentosa (RP). ADX-2191 is a methotrexate for intravitreal injection.

Aldeyra Secures US Orphan Drug Tag For Its Retinitis Pigmentosa Candidate

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for ADX-2191 (methotrexate for intravitreal injection) for the treatment of retinitis pigmentosa (RP). There are no approved drug treatments for patients with RP, a clinical group of rare genetic eye diseases characterized by retinal cell death and loss of vision. The disease affects an estimated 82,000-110,00

Aldeyra Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-2191 to Treat Retinitis Pigmentosa

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call at 8:00 a.m. ET Thursday, August 5, 2021 to report financial results for the quarter ended June 30, 2021 and discuss recent business highlights. The dial-in numbers are (866) 211-4098 for domestic callers and (647) 689-6613 for international callers. The Conference ID number is 4968588. A live webcast of the conference call will also be available on the Investors & Media page o

Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Second-Quarter 2021 Financial Results and Discuss Recent Business Highlights

The FDA grants an Orphan Drug designation to Aldeyra's (ALDX) ADX-2191 for the treatment of primary vitreoretinal lymphoma.

Aldeyra's (ALDX) ADX-2191 Gets Orphan Drug Tag for Rare Cancer

The FDA has granted Orphan Drug Designation to Aldeyra Therapeutics Inc's (NASDAQ: ALDX) ADX-2191 (methotrexate for intravitreal injection) for primary vitreoretinal lymphoma (PVRL).  PVRL is a rare ocular lymphoid malignancy consisting of a subset of primary central system lymphoma (PCNSL) and the most common type of intraocular lymphoma.

Aldeyra Stock Trading Higher On FDA Orphan Drug Tag For Primary Vitreoretinal Lymphoma Candidate

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company for ADX-2191 (methotrexate for intravitreal injection) for the treatment of primary vitreoretinal lymphoma (PVRL). There are no approved treatments for PVRL, a rare, aggressive, high-grade cancer that affects approximately 2,800 people in the United States, with approximately 600 new cases diagn

Aldeyra Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-2191 to Treat Primary Vitreoretinal Lymphoma

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases, today announced that the company was added to the broad-market Russell 3000® Index and the small-cap Russell 2000® Index, effective after the U.S. market opened on June 28, 2021, as part of the 2021 Russell reconstitution. The annual reconstitution of the Russell indexes captures the 4,000 largest US s

Aldeyra Therapeutics Joins the Russell 2000® and Russell 3000® Indexes

Stellar P values in late stage dry eye disease and allergic conjunctivitis studies.

News for Aldeyra Therapeutics Stock (ALDX)